Index of /wp-content/uploads/2021/11/
| Name | Last Modified | Size |
|---|---|---|
 Parent Directory | ||
 Bempedoic-acid-Plain-English-Summary.-20026.docx-1.pdf | 2023-03-09 11:31 | 340k |
| Bempedoic-acid-Plain-English-Summary.-20026.docx.pdf | 2023-03-09 11:31 | 340k |
| Bempedoic-acid-Technical-summary.-20026-1.pdf | 2023-03-09 11:31 | 528k |
| Bempedoic-acid-Technical-summary.-20026.pdf | 2023-03-09 11:31 | 528k |
| Larotrectinib-technical-summary-FINAL-221021.pdf | 2023-03-09 11:31 | 636k |
| Plain-English-Summary-daratumumab.-HTA-ID-20025.pdf | 2023-03-09 11:31 | 340k |
| Plain-English-Summary-Larotrectinib-Final-1.pdf | 2023-03-09 11:31 | 340k |
| Plain-English-Summary-Larotrectinib-Final.pdf | 2023-03-09 11:31 | 340k |
| Plain-English-Summary.pdf | 2023-03-09 11:31 | 340k |
| RR-Submission-template-v-2.0.docx | 2023-03-09 11:31 | 112k |
| Summary-darborthaldex-HTAID_20025-Final.pdf | 2023-03-09 11:31 | 632k |
| Technical-Summary-Pegylated-liposomal-irinotecan-20028.docx.pdf | 2023-03-09 11:31 | 672k |
| Tildrakizumab-Plain-English-Summary-19029.pdf | 2023-03-09 11:31 | 412k |
| Tildrakizumab-Technical-Summary-19029.pdf | 2023-03-09 11:31 | 624k |